Skip to main content
. 2021 Aug 30;144(19):1543–1552. doi: 10.1161/CIRCULATIONAHA.121.057063

Figure 3.

Figure 3.

Primary end point results. A, Kaplan-Meier estimated rates of the primary safety end point in the prespecified analysis population (per protocol). B, Primary effectiveness end point in the prespecified analysis populations (intention-to-treat). C, Distribution of residual jet at 45 days for the images analyzed by the echocardiography core laboratory in the prespecified analysis population (success as randomized).